Coloplast CEO on FDA ban: "We are disappointed"

CEO in Coloplast Kristian Villumsen is disappointed over FDA's decision to ban the company's transvaginal synthetic mesh product although the prohibition only has marginal impact on Coloplast's revenue. However, analyst calls the case "bad news" for the company.

Kristian Villumsen, CEO in Coloplast. Photo: Coloplast PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles